The Global Central Nervous System (CNS) Biomarkers market is estimated to rise at a CAGR of 10.49%, increasing its value from $3587 million to $8756 million over the forecast period of 2017-2025. Factors like funding for the research and development framework programs, increasing applications of metabolomics, genomics, bioinformatics and proteomics, and an upsurge in biomarker market are primarily driving the market growth. Also, the fact that obesity has to become a serious concern worldwide and the escalating number of public-private corporations globally are presenting the market with potential growth opportunities.

Enzo Biochem, an integrated bioscience company, has been focusing on developing proprietary technologies that deals with applications like oral immune regulation, cell signaling pathway, and gene analysis technology. Another company, Thermo Fisher Scientific Inc provides products and services under five principal brands that include: Applied Bio systems, Fisher Scientific, Invitrogen, Thermo Scientific, and Unity Lab Services. The other eminent market players include Alseres Pharmaceuticals Inc, Acumen Pharmaceuticals Inc, Apitope International Avacta Group Plc, Aposense, Avid Radiopharmaceuticals Inc, Diagenic Asa, Banyan Biomarkers, EKF Diagnostics, Myriad Rbm, Inc (Subsidiary Of Myriad Genetics), Exonhit Therapeutics, and Proteome Sciences.

Learn More>>>http://www.insightpharmareports.com/Affiliated-Reports/Inkwood-Research/Global-Central-Nervous-System-Biomarkers/